

Andreas Peyrl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5141783/publications.pdf>

Version: 2024-02-01

73
papers

1,545
citations

471371

17
h-index

345118

36
g-index

75
all docs

75
docs citations

75
times ranked

3042
citing authors

#	ARTICLE	IF	CITATIONS
1	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	6.0	461
2	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	13.7	273
3	Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 511-517.	0.8	98
4	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. <i>Cancer Cell</i> , 2020, 38, 44-59.e9.	7.7	94
5	Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. <i>Journal of Neuro-Oncology</i> , 2014, 120, 139-145.	1.4	58
6	Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2019, 9, 1436.	1.3	50
7	Laser Ablation-Inductively Coupled Plasma Time-of-Flight Mass Spectrometry Imaging of Trace Elements at the Single-Cell Level for Clinical Practice. <i>Analytical Chemistry</i> , 2019, 91, 8207-8212.	3.2	41
8	Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [¹⁸ F]FDG-PET imaging. Is it of value in asymptomatic patients?. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26733.	0.8	35
9	Pharmacokinetics and Safety of Intrathecal Liposomal Cytarabine in Children Aged ≥ 3 Years. <i>Clinical Pharmacokinetics</i> , 2009, 48, 265-271.	1.6	34
10	Feasibility and tolerability of bevacizumab in children with primary CNS tumors. <i>Pediatric Blood and Cancer</i> , 2010, 54, 681-686.	0.8	33
11	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. <i>Neuro-Oncology</i> , 2017, 19, 1183-1194.	0.6	31
12	Determination of a Tumor-Promoting Microenvironment in Recurrent Medulloblastoma: A Multi-Omics Study of Cerebrospinal Fluid. <i>Cancers</i> , 2020, 12, 1350.	1.7	30
13	Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing. <i>Clinical Pharmacokinetics</i> , 2014, 53, 165-173.	1.6	28
14	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. <i>Acta Neuropathologica Communications</i> , 2020, 8, 78.	2.4	28
15	High impact of miRNA-4521 on FOXM1 expression in medulloblastoma. <i>Cell Death and Disease</i> , 2019, 10, 696.	2.7	27
16	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma. <i>Acta Neuropathologica Communications</i> , 2019, 7, 128.	2.4	26
17	From Symptom to Diagnosis – The Prediagnostic Symptomatic Interval of Pediatric Central Nervous System Tumors in Austria. <i>Pediatric Neurology</i> , 2017, 76, 27-36.	1.0	24
18	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. <i>Journal of Personalized Medicine</i> , 2020, 10, 290.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Evaluation and optimization of common lipid extraction methods in cerebrospinal fluid samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1153, 122271.	1.2	16
20	Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 292.	1.1	15
21	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. <i>Acta Neuropathologica</i> , 2021, 142, 339-360.	3.9	14
22	Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas. <i>Acta Neurochirurgica</i> , 2021, 163, 2025-2035.	0.9	13
23	Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. <i>Pediatric Blood and Cancer</i> , 2009, 52, 476-480.	0.8	11
24	Potential Importance of Early Focal Radiotherapy Following Gross Total Resection for Long-Term Survival in Children With Embryonal Tumors With Multilayered Rosettes. <i>Frontiers in Oncology</i> , 2020, 10, 584681.	1.3	11
25	GCT-76. 24Gy WHOLE VENTRICULAR RADIOTHERAPY ALONE IS SUFFICIENT FOR DISEASE CONTROL IN LOCALISED GERMINOMA IN CR AFTER INITIAL CHEMOTHERAPY – EARLY RESULTS OF THE SIOP CNS GCT II STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii343-iii344.	0.6	8
26	Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 75-77.	0.7	7
27	Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma?. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 552-559.	1.0	7
28	Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents. <i>PLoS ONE</i> , 2020, 15, e0230781.	1.1	7
29	Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. <i>Drugs in R and D</i> , 2017, 17, 469-474.	1.1	6
30	MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A MEMMAT-BASED ANTIANGIOGENIC APPROACH. <i>Neuro-Oncology</i> , 2020, 22, iii397-iii397.	0.6	5
31	MBCL-27. RESPONSE OF RECURRENT MALIGNANT CHILDHOOD CNS TUMORS TO A MEMMAT BASED METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY VARIES DEPENDENT ON TUMOR TYPE: EXPERIENCE IN 71 PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, i122-i122.	0.6	4
32	Self-Care Strategies and Job Satisfaction in Pediatricians: What We Can Do to Prevent Burnout? Results of a Nationwide Survey. <i>Frontiers in Pediatrics</i> , 2021, 9, 722356.	0.9	3
33	Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report. <i>Frontiers in Neuroscience</i> , 2022, 16, 810645.	1.4	3
34	Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 617-627.	1.1	3
35	DIPC-60. Avapritinib for targeting PDGFRA in H3K27M – mutated diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i32-i32.	0.6	3
36	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.0	2

#	ARTICLE	IF	CITATIONS
37	EAPH-11. INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE, AQUEOUS CYTARABINE AND TOPOTECAN IS FEASIBLE AND SAFE: EXPERIENCE IN 26 PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i67-i67.	0.6	2
38	Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage. <i>Neurosurgery</i> , 2020, 86, 478-484.	0.6	2
39	INN-17. RESPONSE TO AVAPRITINIB IN A PEDIATRIC SPINAL CORD H3K27M-MUTANT GLIOMA PATIENT. <i>Neuro-Oncology</i> , 2021, 23, vi108-vi108.	0.6	2
40	Evaluating the diagnostic validity of the cerebellar cognitive affective syndrome (CCAS) in pediatric posterior fossa tumor patients. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	2
41	How can we optimize the long-term outcome in children with intracranial cavernous malformations? A single-center experience of 61 cases. <i>Neurosurgical Review</i> , 2022, 45, 3299-3313.	1.2	2
42	BMET-08. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE IS FEASIBLE AND SAFE: EXPERIENCE IN 57 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2016, 18, vi27-vi28.	0.6	1
43	Innovative therapy concepts for pediatric brain tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 260-264.	0.3	1
44	Protein Profiling of the Supratentorial Primitive Neuroectodermal Tumor (PNET) Cell Line PFSK-1. <i>Cancer Genomics and Proteomics</i> , 2004, 1, 125-136.	1.0	1
45	GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results. <i>Neuro-Oncology</i> , 2022, 24, i56-i57.	0.6	1
46	Sociocultural variables have a major impact on participation in patients treated for paediatric posterior fossa tumours. <i>Child: Care, Health and Development</i> , 0, , .	0.8	1
47	ANGI-14UPDATE ON A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY FOR RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. <i>Neuro-Oncology</i> , 2015, 17, v44.1-v44.	0.6	0
48	MBCL-28. PREDISPOSITION OF WNT-ACTIVATED MEDULLOBLASTOMA FOR PRIMARY INTRATUMORAL HEMORRHAGE. <i>Neuro-Oncology</i> , 2018, 20, i122-i122.	0.6	0
49	MBCL-40. UNFAVORABLE CLINICAL COURSE OF A WNT-ACTIVATED MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i125-i126.	0.6	0
50	NSRG-19. CSF DISTURBANCES AFTER TRANSCALLOSAL RESECTION: ARE THERE PREDICTING FACTORS?. <i>Neuro-Oncology</i> , 2018, 20, i149-i149.	0.6	0
51	INN-36. A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY MAY PROLONG SURVIVAL FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. <i>Neuro-Oncology</i> , 2018, 20, vi145-vi145.	0.6	0
52	QOL-43. CEREBELLAR MUTISM, NEUROCOGNITIVE AND ACADEMIC OUTCOME IN A CONSECUTIVE SAMPLE OF PEDIATRIC CEREBELLAR TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, i166-i166.	0.6	0
53	RARE-12. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). <i>Neuro-Oncology</i> , 2019, 21, vi223-vi224.	0.6	0
54	PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. <i>Neuro-Oncology</i> , 2019, 21, vi194-vi194.	0.6	0

#	ARTICLE	IF	CITATIONS
55	An adolescent with herpes simplex encephalitis, presenting with mild symptoms and rapid deterioration: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2097714.	0.2	0
56	RARE-20. A RARE CASE OF A PRIMARY CENTRAL NERVOUS SYSTEM NEUROENDOCRINE CARCINOMA AND SUCCESSFULL THERAPY IN A FIVE-YEAR-OLD CHILD. <i>Neuro-Oncology</i> , 2021, 23, i45-i45.	0.6	0
57	DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii284-iii284.	0.6	0
58	ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). <i>Neuro-Oncology</i> , 2020, 22, iii324-iii325.	0.6	0
59	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii312.	0.6	0
60	HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii351-iii352.	0.6	0
61	EPCO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. <i>Neuro-Oncology</i> , 2020, 22, ii76-ii77.	0.6	0
62	QOL-35. School reentry of children and adolescents with a brain tumor: can we improve family-school-hospital cooperation? An analysis of supportive and inhibiting factors as a result of a pilot project. <i>Neuro-Oncology</i> , 2022, 24, i141-i141.	0.6	0
63	HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations. <i>Neuro-Oncology</i> , 2022, 24, i73-i73.	0.6	0
64	QOL-27. Sociocultural variables have a major impact on participation in patients treated for pediatric posterior fossa tumors. <i>Neuro-Oncology</i> , 2022, 24, i139-i139.	0.6	0
65	PATH-09. Liquid biopsy of cerebrospinal fluid enables detecting and monitoring of <i>MYC/MYC</i> amplification in pediatric CNS malignancies. <i>Neuro-Oncology</i> , 2022, 24, i160-i160.	0.6	0
66	SWK-06. Structured transition from pediatric neuro-oncology to adult survivorship follow-up care - Can we close the gap?. <i>Neuro-Oncology</i> , 2022, 24, i181-i182.	0.6	0
67	DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors. <i>Neuro-Oncology</i> , 2022, 24, i34-i35.	0.6	0
68	SURG-02. The site of origin of medulloblastoma: Does the neurosurgical perspective support the current concept from molecular data?. <i>Neuro-Oncology</i> , 2022, 24, i142-i142.	0.6	0
69	ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets. <i>Neuro-Oncology</i> , 2022, 24, i52-i52.	0.6	0
70	QOL-30. Positive Effects of a psychological preparation program for MRI in children with cognitive issues – how to best meet the patients’ needs. <i>Neuro-Oncology</i> , 2022, 24, i140-i140.	0.6	0
71	GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy – final of the SIOP CNS GCT II study. <i>Neuro-Oncology</i> , 2022, 24, i56-i56.	0.6	0
72	SWK-05. Clinical social work in pediatric neuro-oncology – A research project on the social dimension using social diagnostics. <i>Neuro-Oncology</i> , 2022, 24, i181-i181.	0.6	0

#	ARTICLE	IF	CITATIONS
73	QOL-24. Evaluating the diagnostic validity & predictive value of the Cerebellar Cognitive Affective Syndrome (CCAS) in pediatric posterior fossa tumour patients. Neuro-Oncology, 2022, 24, i138-i139.	0.6	0